BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
I think there are more similarities and differences. And from the outcomes that we have seen, I don't really see any difference. So I use pembrolizumab. I like the dosing schedule, and I'm very comfortable with it.
0
💬
0
Comments
Log in to comment.
There are no comments yet.